SCIENCE AND TECHNOLOGY
AI in drug discovery and translational medicine
“Generating structurally informed disease-associated protein interactomes, designing cyclic peptide and cryptic epitope-specific antibody ”
PARTNERING - COLLABORATION MAKES US BETTER!
By harnessing an AI model, AgnistaBio enables its partners to swiftly
(1) discover highly developable (a) human antibody or cyclic peptide against target protein of interest, including untargetable proteins, such as GPCRs, and their cryptic epitopes or multiprotein complex specific epitopes, and (b) cyclic peptide.
(2) identify disease-associated structurally informed interactomes (interacting/regulating proteins/enzymes against the target protein and its detailed 4D structures) for accelerating drug design on a proteome scale in short lead time.
AgnistaBio is seeking pharma/biotech companies to license or co-develop its potential therapeutic candidates.
Drug Development
AgnistaAI accelerates the discovery of novel therapeutic antibodies and cyclic peptides as well as uncovers their unexpected interacting proteins to avoid potential side effects in clinics.
